Alpha 2.0
Login Register
» Authors » Vinod Pullarkat

Vinod Pullarkat

Explore the profile of Vinod Pullarkat including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 184
Citations 4408
Followers 0
Related Specialties
Hematology
Oncology
General Surgery
Top 10 Co-Authors
Ibrahim Aldoss
Guido Marcucci
Stephen J Forman
Ryotaro Nakamura
Amandeep Salhotra
Haris Ali
Ahmed Aribi
Anthony Stein
Monzr M Al Malki
Anthony S Stein
Published In
Am J Hematol
Biol Blood Marrow Transplant
Leuk Lymphoma
Leuk Res
Blood Adv
Affiliations
Soon will be listed here.
Recent Articles
1.
Impact of hyperhydration on fluid overload and hematopoietic cell transplant after post-transplant cyclophosphamide-based graft-versus-host-disease prophylaxis
Samuels D, Yao J, Samara Y, Yang D, Mokhtari S, Tiemann K, et al.
Front Immunol . 2025 Mar; 16:1543099. PMID: 40051639
Introduction: Hemorrhagic cystitis (HC) is an early complication after hematopoietic cell transplant (HCT) with post-transplant cyclophosphamide (PTCy). Hyperhydration can reduce HC, but may lead to fluid overload (FO), which has...
2.
Melphalan-based conditioning with post-transplant cyclophosphamide for peripheral blood stem cell transplantation: donor effect
Koller P, Othman T, Yang D, Mokhtari S, Samara Y, Blackmon A, et al.
Bone Marrow Transplant . 2025 Feb; PMID: 40016513
Fludarabine and melphalan (FM) conditioning offers effective disease control with an acceptable toxicity profile. Post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis has improved transplant outcomes. We retrospectively reviewed patients...
3.
Treatment of Relapsed/Refractory AML-Novel Treatment Options Including Immunotherapy
Moore C, Stein A, Fathi A, Pullarkat V
Am J Hematol . 2025 Feb; 100 Suppl 2:23-37. PMID: 39960017
Acute myeloid leukemia is a molecularly heterogenous disease caused by the rapid expansion and impaired differentiation of malignant myeloid progenitors. Overall, outcomes remain poor, and more than half of patients...
4.
Application of RNA-Based Next-Generation Sequencing Fusion Assay for Hematological Malignancies
Fei F, Telatar M, Tomasian V, Chang L, Gust M, Yew H, et al.
Int J Mol Sci . 2025 Jan; 26(2). PMID: 39859151
Recurrent fusions drive the pathogenesis of many hematological malignancies. Compared to routine cytogenetic/fluorescence in situ hybridization (FISH) studies, the RNA-based next-generation sequencing (NGS) fusion assay enables the identification of both...
5.
Fludarabine melphalan reduced intensity conditioning vs radiation-based myeloablative conditioning in patients undergoing allogeneic transplantation for acute myeloid leukemia with measurable residual disease
Blackmon A, Afkhami M, Yang D, Mokhtari S, Samara Y, Pourhassan H, et al.
Bone Marrow Transplant . 2024 Dec; 60(2):165-174. PMID: 39695333
Patients with AML and measurable residual disease (MRD) undergoing allogeneic hematopoietic cell transplantation (HCT) may benefit from myeloablative conditioning (MAC) when feasible to reduce relapse risk. Fludarabine-Melphalan (FluMel) is a...
6.
Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria
Dingli D, De Castro Iii C, Koprivnikar J, Kulasekararaj A, Maciejewski J, Mulherin B, et al.
Hematology . 2024 Dec; 29(1):2329030. PMID: 39665683
Introduction: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, non-malignant hematologic disease characterized by complement-mediated hemolysis (with or without hemoglobinuria), fatigue, increased susceptibility to thrombosis, and bone marrow dysfunction. The...
7.
Venetoclax in combination with a pediatric-inspired regimen for the treatment of newly diagnosed adults with Philadelphia chromosome-negative acute lymphoblastic leukemia
Aldoss I, Zhang J, Shimamoto K, Saygin C, Robbins M, Agrawal V, et al.
Haematologica . 2024 Nov; PMID: 39506897
BCL-2 protein overexpression, common in B-cell acute lymphoblastic leukemia (B-ALL), including the Philadelphia (Ph)-like subtype, mediates leukemic cell survival. We treated 24 patients with 14 days of BCL-2 inhibitor, venetoclax,...
8.
Delaying pegaspargase during induction in adults with acute lymphoblastic leukaemia is associated with lower risk of high-grade hepatotoxicity without adversely impacting outcomes
Tinajero J, Xu S, Ngo D, Li S, Palmer J, Nguyen T, et al.
Br J Haematol . 2024 Nov; 206(3):868-875. PMID: 39505575
Pegaspargase is a key drug for the treatment of younger adults with acute lymphoblastic leukaemia (ALL). Pegaspargase-associated hepatotoxicity is most common during induction, and its incidence increases with age and...
9.
Lower-intensity CPX-351 plus venetoclax induction for adults with newly diagnosed AML unfit for intensive chemotherapy
Uy G, Pullarkat V, Baratam P, Stuart R, Walter R, Winer E, et al.
Blood Adv . 2024 Oct; 8(24):6248-6256. PMID: 39418644
Preclinical data suggest a rationale for combining CPX-351, a dual-drug liposomal encapsulation of daunorubicin and cytarabine, with venetoclax, a B-cell lymphoma-2 inhibitor. This phase 1b study evaluated lower-intensity CPX-351 combined...
10.
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL
Roloff G, Aldoss I, Kopmar N, Lin C, Dekker S, Gupta V, et al.
J Clin Oncol . 2024 Oct; 43(5):558-566. PMID: 39418622
Purpose: On the basis of the results of the ZUMA-3 trial, brexucabtagene autoleucel (brexu-cel), a CD19-directed chimeric antigen receptor T-cell therapy, gained US Food and Drug Administration approval in October...